Novo Nordisk Aims for Wegovy Approval in China in 2023, Faces Competition from Lilly's GLP-1 Drugs
• Novo Nordisk expects approval of its weight-loss drug Wegovy in China this year • Plans to initially launch Wegovy in China with capped volumes, focusing on out-of-pocket paying patients • Wegovy belongs to the GLP-1 class of drugs used to treat obesity and diabetes • No generics of GLP-1 drugs expected to be approved in China before 2028 • Novo Nordisk faces competition in GLP-1 market from Lilly's Mounjaro and Zepbound